Sudeep Pharma Ltd

Sudeep Pharma Ltd share price rallied 9.21% to Rs 1116.05 after the company's net profit jumped 27.64% to Rs 51.81 crore, while revenue from operations gained significantly 24.28% to Rs 196.7 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, gaining 4.30%. It has marginally improved by 3.87% over last one week and gained upto 0.06% in last one month while the market capitalization of Sudeep Pharma Ltd has significantly gained 15.62% and 26.91% in the same period respectively. Profit before tax (PBT) of Sudeep Pharma Ltd stood at Rs 71.03 crore in Q3 FY26, jumping 19.32% year-on-year, and expanding by 30.83% quarter-on-quarter. EBITDA came in at Rs 67 crore, surging by 48.51% YoY and rallying 35.99% sequentially. Total expenses jumped by 20.01% to Rs 128.84 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 71.37 crore, growing marginally by 3.72% YoY, while employee benefits expense was at Rs 15.61 crore, improving by 8.86% YoY. For the TTM ended FY26, revenue from operations surged 27.94% to Rs 642.26 crore, while net profit saw a strong growth of 25.63% to Rs 174.28 crore, compared to previous TTM. EBITDA surged by 18384% to Rs 193.31 crore, and PBT witnessed a strong rise of 24.73% to Rs 228.07 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 69.55 crore in FY26, as against Rs 48.73 crore in FY25. Sudeep Pharma Ltd surged by 44.25% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 13.45% during the same period.

Sudeep Pharma Ltd share price gained 3.95% to Rs 1021.9 after the company's net profit surged by 27.64% to Rs 51.81 crore, while revenue from operations gained significantly 24.28% to Rs 196.7 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.44 lakh crore, rising 4.11%. It has inched up 3.17% over last one week and eased lower by 0.26% in last one month while the market capitalization of Sudeep Pharma Ltd has marginally improved by 5.20% and 19.24% in the same period respectively. Profit before tax (PBT) of Sudeep Pharma Ltd stood at Rs 71.03 crore in Q3 FY26, jumping 19.32% year-on-year, and rallying 30.83% quarter-on-quarter. EBITDA came in at Rs 67 crore, surging by 48.51% YoY and expanding by 35.99% sequentially. Total expenses jumped by 20.01% to Rs 128.84 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 71.37 crore, growing marginally by 3.72% YoY, while employee benefits expense was at Rs 15.61 crore, improving by 8.86% YoY. For the TTM ended FY26, revenue from operations surged 27.94% to Rs 642.26 crore, while net profit saw a strong growth of 25.63% to Rs 174.28 crore, compared to previous TTM. EBITDA soared by 18384% to Rs 193.31 crore, and PBT soared 24.73% to Rs 228.07 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 69.55 crore in FY26, as against Rs 48.73 crore in FY25. Sudeep Pharma Ltd rallied 32.08% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.19% during the same period.

Sudeep Pharma Limited will hold a board meeting on Wednesday, October 28, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, the company said in a filing with the National Stock Exchange of India Limited and BSE Limited. The trading window for insiders was closed from October 1, 2026, and will remain closed until October 30, 2026.

Sudeep Pharma Limited informed the National Stock Exchange of India Limited and BSE Limited that MUFG Intime India Private Limited, formerly Link Intime India Private Limited, confirmed that no demat requests were received for processing during the quarter ended September 30, 2026, as all shares of Sudeep Pharma Limited are held in electronic mode.

Sudeep Pharma Limited announced that Mr. Sendhil Pani, Managing Director of Sudeep Pharma USA Inc., a wholly owned subsidiary, will no longer serve as a Senior Management Personnel (SMP) of the company due to the completion of his contractual arrangements, effective October 2, 2026.

Sudeep Pharma Limited will close its trading window for designated persons from October 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter and half year ending September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Sudeep Pharma Ltd share price inched up 0.10% to Rs 869.45. The Company's net profit fell 16.38% to Rs 40.59 crore, while revenue from operations reduced 13.20% to Rs 158.27 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, easing 6.18%. It has improved by 0.41% over last one week and rose by 11.45% in last one month while the market capitalization of Sudeep Pharma Ltd has softened by 1.06% and 29.50% in the same period respectively. Profit before tax (PBT) of Sudeep Pharma Ltd stood at Rs 54.29 crore in Q2 FY26, rallying 23.19% year-on-year, and dropping 13.40% quarter-on-quarter. EBITDA came in at Rs 49 crore, expanding by 27.77% YoY and falling 11.95% sequentially. Total expenses reduced by 13.16% to Rs 107.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 68.81 crore, slightly declining by 3.28% YoY, while employee benefits expense was at Rs 14.34 crore, witnessing a strong rise of 36.31% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 27.94% to Rs 642.26 crore, while net profit soared by 25.63% to Rs 174.28 crore, compared to previous TTM. EBITDA surged by 18384% to Rs 193.31 crore, and PBT surged 24.73% to Rs 228.07 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 69.55 crore in FY26, as against Rs 48.73 crore in FY25. Sudeep Pharma Ltd jumped 12.38% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.20% during the same period.

Sudeep Pharma Ltd share price inched up 0.10% to Rs 869.45. The Company's net profit contracted by 16.38% to Rs 40.59 crore, while revenue from operations declined 13.20% to Rs 158.27 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.75 lakh crore, easing 6.21%. It has improved by 1.69% over last one week and rose by 11.78% in last one month while the market capitalization of Sudeep Pharma Ltd has marginally improved by 0.85% and 28.91% in the same period respectively. Profit before tax (PBT) of Sudeep Pharma Ltd stood at Rs 54.29 crore in Q2 FY26, expanding by 23.19% year-on-year, and dropping 13.40% quarter-on-quarter. EBITDA came in at Rs 49 crore, rallying 27.77% YoY and falling 11.95% sequentially. Total expenses reduced by 13.16% to Rs 107.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 68.81 crore, softening by 3.28% YoY, while employee benefits expense was at Rs 14.34 crore, soaring 36.31% YoY. For the TTM ended FY26, revenue from operations surged 27.94% to Rs 642.26 crore, while net profit soared by 25.63% to Rs 174.28 crore, compared to previous TTM. EBITDA surged by 18384% to Rs 193.31 crore, and PBT soared 24.73% to Rs 228.07 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 69.55 crore in FY26, as against Rs 48.73 crore in FY25. Sudeep Pharma Ltd jumped 12.26% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.94% during the same period.

Sudeep Pharma will hold a meeting of the Board of Directors of the Company on 4 August 2026.

Sudeep Pharma announced that the 37th Annual General Meeting(AGM) of the company will be held on 4 August 2026.